trending Market Intelligence /marketintelligence/en/news-insights/trending/a8V51VF5_eyvUHusA2PtaA2 content esgSubNav
In This List

US FDA approves clinical trials of Cerenis drug for liver disease

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


US FDA approves clinical trials of Cerenis drug for liver disease

The U.S. FDA approved has given the go-ahead for clinical trials of Cerenis Therapeutics Holding SA's CER-209 drug candidate.

The investigational new drug application for CER-209 involves plans for a phase 1 clinical study in healthy volunteers for the clinical investigation of nonalcoholic fatty liver disease and nonalcoholic steato-hepatitis.

Cerenis intends to start enrollment for the clinical study in the first quarter of 2017.